Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants, either men or women are ≥ 18 years of age.~2. Patients must have at least one hard to heal wound of different etiologies (venous insufficiency, lymphatic insufficiency, neuropathic wounds or diabetic ulcers, post- operative and post-traumatic chronic wounds) located on the leg shin or foot.~3. The wound is refractive to healing at least 4 weeks prior to treatment, although treated by routine practice.~4. Wound area size is in the range of: 3 - 36 square centimeters.~5. Patients defined as grade C or above on the granulometer scale (see section 6.5.1).~6. Participants understand the nature of the procedure and provide written informed consent prior to any study procedure.~7. Women of child bearing potential must use adequate birth-control precautions.~Exclusion Criteria:~1. Clinically significant arterial vascular disease with ABI index \<0.45 if the peripheral pulse is not palpable, or flatted PVR in case of non palpable arteries.~2. Clinical evidence for presence of infection in the soft tissue, joint and/or bone (osteomyelitis).~3. Wound has Non-viable tissue which covers more than 50% of the wound area.~4. Patients with skin disorders unrelated to the ulcer that are presented adjacent to the wound.~5. The wound penetrates into deep organs and involves bone, tendon or joint~6. Wound with sinus tracts~7. Patients are receiving, or have received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.~8. Treatment with a dressing containing growth factors or other biological dressings within 15 days, prior to the screening visit.~9. Patients that have a history of alcohol or drug abuse within the last two years.~10. Female patients who are pregnant or nursing, or of childbearing potential and are not using adequate contraception.~11. Participation in another clinical trial within 30 days prior to the Screening Visit or during this study.~12. Clinically significant and/or uncontrolled condition or other significant medical disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).